Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Docusign Inc (DOCU) vs Sana Biotechnology Inc (SANA) Price & Performance

Docusign IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Docusign Inc vs Sana Biotechnology Inc — how do they compare? Docusign Inc trades at $59.42 (market cap $11.33B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Docusign Inc is far larger — about 10× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.

DOCUSANA
Market Cap
$11.33B$1.13B
Sector
TechnologyHealth
52-Week High
$85.01$5.92
52-Week Low
$41.75$2.68
Enterprise Value
$10.70B$1.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Docusign Inc

DOCU trades at $57.82, down 3.05% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding the $0.994 estimate. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. Recent news highlights institutional trading activity and positive analyst coverage on growth prospects.

The outlook for DOCU is mixed; fundamentals show robust revenue growth and expanding margins, but valuation multiples like a P/E of 38.53 suggest premium pricing. Key risks include competitive pressures in e-signature software and reliance on subscription revenue. Analyst consensus is cautious with a hold-heavy rating, though the $55.40 price target implies limited upside from current levels.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.

Returns comparison

Trailing returns across standard periods

About Docusign Inc

DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.

Read more on DOCU

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA